Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Chimeric Therapeutics Ltd. ( (AU:CHM) ) is now available.
Chimeric Therapeutics Limited has announced the quotation of 200,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of May 28, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support its ongoing development projects, potentially strengthening its position in the competitive biotechnology market.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited operates in the biotechnology industry, focusing on developing innovative therapies for cancer treatment. The company specializes in chimeric antigen receptor T cell (CAR-T) therapies, aiming to provide advanced solutions for patients with difficult-to-treat cancers.
Technical Sentiment Signal: Sell
Current Market Cap: A$8.06M
See more data about CHM stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue